Hot Features
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatm... Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 420 | 1.0E-6 | CS |
| 12 | -9.9E-5 | -99 | 0.0001 | 0.00025 | 1.0E-6 | 1680 | 0.00010084 | CS |
| 26 | -9.9E-5 | -99 | 0.0001 | 0.0005 | 1.0E-6 | 2835 | 0.00022627 | CS |
| 52 | -0.000499 | -99.8 | 0.0005 | 0.0006 | 1.0E-6 | 3836 | 0.0003991 | CS |
| 156 | -0.160499 | -99.999376947 | 0.1605 | 0.2475 | 1.0E-6 | 33320 | 0.04860254 | CS |
| 260 | -0.160499 | -99.999376947 | 0.1605 | 0.2475 | 1.0E-6 | 33320 | 0.04860254 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.